CDC advises using Sanofi, AstraZeneca RSV drug for babies.
Protecting Infants Against RSV: A Breakthrough Recommendation
The U.S. Centers for Disease Control and Prevention (CDC) made an exciting announcement on Aug. 3. They recommended the use of a new monoclonal antibody, developed by Sanofi and AstraZeneca, to safeguard infants against respiratory syncytial virus (RSV).
The CDC’s advisory committee unanimously voted to include the nirsevimab antibody drug, known as Beyfrotus, in the Vaccines for Children program. This means that eligible children will have access to Beyfrotus at no cost.
“Today, we have turned the corner on the threat of RSV to our youngest, most vulnerable population,” said Thomas Triomphe, executive vice president for vaccines at Sanofi.
Who Can Benefit from Beyfrotus?
Beyfrotus is recommended for infants under 8 months old entering their first RSV season. Additionally, it is also suitable for children between 8 and 19 months old who are at a higher risk of severe illness and entering their second RSV season.
The CDC highlighted that Beyfrotus is a long-acting monoclonal antibody, which has been proven to reduce the risk of hospitalizations and healthcare visits for RSV in infants by about 80 percent.
Beyfrotus received approval from the Food and Drug Administration (FDA) last month for preventing RSV disease in infants. The FDA supported its safety and efficacy based on three clinical trials with favorable results.
Sanofi stated, “Across all clinical endpoints, a single dose of Beyfrotus delivered high, consistent, and sustained efficacy against RSV lower respiratory tract disease extending through five months.”
Furthermore, Beyfrotus offers rapid protection without requiring activation of the immune system. It can be administered as an intramuscular injection using a single-dose pre-filled syringe, according to the CDC.
Expert Approval and Availability
CDC Director Dr. Mandy Cohen endorsed the recommendations on Thursday. She believes that the new RSV immunization will provide parents with “a powerful tool” to protect their children against the threat of RSV disease.
As we approach the respiratory virus season this fall, it’s crucial to utilize these new tools available to help safeguard our little ones.
